###### Strengths and limitations of this study

-   This is the first objective evidence of inconsistencies in approach by a national guideline developer.

-   This supports commentator suggestion that even without good evidence a group will prefer consensus.

-   Adds to the current debate about how guidelines might be developed in the future.

-   The study is limited to only one set of national guidelines, that is, the Scottish Intercollegiate Guideline Network (SIGN).

-   Reasons for the differences in quality of evidence preferred by the guideline development groups are unclear.

Introduction {#s1}
============

The Scottish Intercollegiate Guidelines Network (SIGN) was founded in 1993. It is a national body, professionally led and publicly funded. SIGN\'s founding principles proposed direct links between evidence and recommendations, offering a brief and succinct quick-reference guide for clinicians.[@R1] Guidelines anticipated presenting brief, evidence-based clinical advice. They have developed into long and authoritative texts used by managers and politicians to inform policy. A formal arrangement between SIGN and the National Institute of Care Excellence (NICE) has existed from 2003. Both have responsibility to consider cost-effectiveness and input to the Quality and Outcomes Framework (QOF).

The WHO recognises that current grades of recommendation ([box 1](#bx1){ref-type="boxed-text"}) may be ambiguous[@R2] and encourages guideline developers to use a system which includes a category 'Use only in the context of research' where doubt exists. Box 1Grades of recommendationAt least one meta-analysis, systematic review, or randomized controlled trial (RCT) rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of resultsA body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; orExtrapolated evidence from studies rated as 1++ or 1+A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; orExtrapolated evidence from studies rated as 2++Evidence level 3 or 4; orExtrapolated evidence from studies rated as 2+

Guideline developers have conflict of interest policies reported as challenging to apply. Where doubt exists, groups of specialists may feel consensus more defensible than acknowledging uncertainty.[@R3]

Even with the best evidence, concerns are expressed about the relevance of guidelines in treating patients with multiple morbidities,[@R4] and the emergence of the phenomenon of reversal,[@R5] [@R6] where established practice, sometimes evidence based, is shown to be suboptimal or harmful. This study looks at the quality of evidence used for SIGN guidelines, and describes a significant trend for some groups to emphasise poorly evidenced recommendations.

Methods {#s2}
=======

SIGN guidelines were accessed online in September 2013. SIGN guidelines were chosen because they are internationally respected, the authors were familiar with their format and they contribute to national government policy. Guidelines that were 'Current' and 'Current 3--7 years, some recommendations, may be out of date.', were included. Those that had been 'Withdrawn', 'Recommendations being updated', 'Need for update being considered' and those with no recommendations were excluded.

SIGN guideline 50 clearly describes an established process for developing guidelines.[@R7] It explains how the process is planned, how it is implemented and by whom. This process is independent of this study, but is stated to be an objective process. SIGN guidelines have four grades of recommendation outlined in [box 1](#bx1){ref-type="boxed-text"}. [Table 1](#BMJOPEN2013004278TB1){ref-type="table"} describes the level of evidence SIGN uses to support the recommendation grading. SIGN guideline development groups vary in size depending on the scope of the topic under consideration, but generally comprise between 15 and 25 members. SIGN states they are aware of the many psychosocial factors, including the problems of overcoming professional hierarchies that can affect small group processes.

###### 

Levels of evidence

  ----- ------------------------------------------------------------------------------------------------------------------------------------------------
  1++   High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias
  1+    Well conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias
  1−    Meta-analyses, systematic reviews, or RCTs with a high risk of bias
  2++   High quality systematic reviews of case-control or cohort studies
  2+    High quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal
  2−    Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
  3     Non-analytic studies eg, case reports and case series
  4     Expert opinion
  ----- ------------------------------------------------------------------------------------------------------------------------------------------------

RCTs, randomised controlled trials.

Three investigators (JRL, AGB and ABB) independently enumerated the level of evidence used by each guideline. They discounted any duplication implicit in text-embedded key recommendations and also implementation recommendations. There were no discrepancies. A statistical analysis of the correlation between the proportion of level D evidence and the total number of recommendations was performed for the 42 guidelines.

Results {#s3}
=======

The 42 guidelines consisted of 2559 pages (including references), ranging from 26 to 161 (median 59.5) pages. The longest guideline, number 116 was 61 pages longer than the next largest. The number of recommendations per page ranged from 0.2 to 1.8 (median 0.7). The number of recommendations per guideline is presented in [table 2](#BMJOPEN2013004278TB2){ref-type="table"}.

###### 

The number of recommendations per guideline

  Number   Number   Name                                                                                                                     Pages   A     B     C     D     Total   Percentage of D
  -------- -------- ------------------------------------------------------------------------------------------------------------------------ ------- ----- ----- ----- ----- ------- -----------------
  133      133      Management of hepatitis C                                                                                                57      20    24    7     52    103     50.5
  132      132      Long-term follow-up of survivors of childhood cancer                                                                     62      0     7     9     14    30      46.7
  131      131      Management of schizophrenia                                                                                              64      10    19    3     15    47      31.9
  130      130      Brain injury rehabilitation in adults                                                                                    68      0     14    7     8     29      27.6
  129      129      Antithrombotics: indication and management                                                                               68      25    11    6     19    61      31.1
  127      127      Management of perinatal mood disorders                                                                                   47      0     5     6     15    26      57.7
  126      126      Diagnosis and management of colorectal cancer                                                                            56      11    19    15    29    74      39.2
  125      125      Management of atopic eczema in primary care                                                                              34      3     5     3     2     13      15.4
  124      124      Management of adult testicular germ cell tumours                                                                         63      6     6     9     21    42      50.0
  123      123      Management of early rheumatoid arthritis                                                                                 27      3     7     2     0     12      0.0
  122      122      Prevention and management of venous thromboembolism                                                                      88      26    15    14    55    110     50.0
  121      121      Diagnosis and management of psoriasis and psoriatic arthritis in adults                                                  65      11    16    6     26    59      44.1
  120      120      Management of chronic venous leg ulcers                                                                                  46      5     3     4     7     19      36.8
  119      119      Management of patients with stroke: identification and management of dysphagia                                           42      0     6     4     20    30      66.7
  118      118      Management of patients with stroke: rehabilitation, prevention and management of complications, and discharge planning   101     21    29    7     21    78      26.9
  117      117      Management of sore throat and indications for tonsillectomy                                                              37      9     3     4     4     20      20.0
  116      116      Management of diabetes                                                                                                   161     57    62    23    16    158     10.1
  115      115      Management of obesity                                                                                                    87      6     11    7     11    35      31.4
  114      114      Non-pharmaceutical management of depression                                                                              37      5     4     0     0     9       0.0
  113      113      Diagnosis and pharmacological management of Parkinson\'s disease                                                         61      12    6     6     4     28      14.3
  112      112      Management of attention deficit and hyperkinetic disorders in children and young people                                  45      6     4     3     4     17      23.5
  111      111      Management of hip fracture in old people                                                                                 49      10    9     8     14    41      34.1
  110      110      Early management of patients with a head injury                                                                          76      1     7     6     17    31      54.8
  109      109      Management of genital Chlamydia trachomatis infection                                                                    40      3     6     9     29    47      61.7
  108      108      Management of patients with stroke or TIA: assessment, investigation, immediate management and secondary prevention      100     42    27    18    14    101     13.9
  107      107      Diagnosis and management of headache in adults                                                                           81      17    16    9     34    76      44.7
  106      106      Control of pain in adults with cancer                                                                                    71      5     7     3     19    34      55.9
  105      105      Management of acute upper and lower gastrointestinal bleeding                                                            57      14    5     2     15    36      41.7
  103      103      Diagnosis and management of chronic kidney disease                                                                       50      9     6     4     3     22      13.6
  102      102      Management of invasive meningococcal disease in children and young people                                                46      1     4     6     26    37      70.3
  99       99       Management of cervical cancer                                                                                            73      1     13    19    29    62      46.8
  97       97       Risk estimation and the prevention of cardiovascular disease                                                             72      16    12    2     4     34      11.8
  96       96       Management of stable angina                                                                                              59      13    10    3     11    37      29.7
  95       95       Management of chronic heart failure                                                                                      55      9     12    1     1     23      4.3
  94       94       Cardiac arrhythmias and coronary heart disease                                                                           42      22    11    13    23    69      33.3
  93       93       Acute coronary syndromes                                                                                                 60      11    14    9     8     42      19.0
  91       91       Bronchiolitis in children                                                                                                42      4     3     6     14    27      51.9
  90       90       Diagnosis and management of head and neck cancer                                                                         92      42    8     26    60    136     44.1
  89       89       Diagnosis and management of peripheral arterial disease                                                                  37      11    2     0     4     17      23.5
  88       88       Management of suspected bacterial urinary tract infection in adults                                                      45      8     10    2     10    30      33.3
  87       87       Management of oesophageal and gastric cancer                                                                             70      3     26    23    28    80      35.0
  61       61       Investigation of postmenopausal bleeding                                                                                 26      2     7     4     4     17      23.5
                    Total                                                                                                                    2559    480   491   318   710   1999    

TIA, transient ischaemic attack.

Of the 1999 recommendations, 480 (24%) were level A, 491(24.6%) were level B, 318 (15.9%) level C and 710 (35.5%) level D. Thus 51.4% were poorly evidenced (C and D) and over a third (D) depend almost entirely on 'expert opinion'. The number of level A recommendations per guideline ranged 0--57 (median 9), level B 2--62 (median 8.5), level C ranged 0--26 (median 6) and level D ranged 0--60 (median 14.5). Four guidelines had no level A evidence.

The proportion of level D evidence increases with the number of recommendations made. This correlation is significant with Kendall\'s τ=0.22 (approximate 95% CI 0.008 to 0.45), p=0.04; and Spearman ρ=0.22 (approximate 95% CI 0.02 to 0.57), p=0.04.

Discussion {#s4}
==========

This study reveals that expert groups who produce long guidelines rely on poor evidence more heavily than others. While this study only looks at SIGN, this study highlights a problem that has escaped national guideline developers, a wide range of professionals and the public to whom these guidelines are applied. National guidelines are useful and important and there is a debate about how evidence is best presented. Guidelines define standards of care, help busy clinicians and allow managers and politicians to develop governance. An American study (using 3 not 4 levels of evidence) similarly found that 48% were 'based on expert opinion, case studies or standards of care';[@R8] we show comparable results for current SIGN guidelines. Where patients are involved in clinical decisions, honestly declaring uncertainty has merit. In the absence of good scientific evidence, recommending a course of action without understanding the circumstances of the individual to whom it is applied seems both risky and, assuming a right to patient choice, unwarranted. Other guidelines that use high levels of poor evidence should evaluate the proportion of poorly evidenced recommendations and seek explanations for such trends.

This study did not examine why longer guidelines use poorer evidence. Groups of experts, indulging in 'group think' may view their own opinion as more authoritative than science can support.[@R9] It has been postulated that there is security in "just doing what everyone else is doing---even if what everyone else is doing isn\'t very good."[@R3] Reliance on expert opinion has a poor track record. Blinded by certainty, expert groups defining established practice have, in the past, perpetuated radical mastectomy instead of conservative surgery, class 1C antiarrhythmics,[@R10] pulmonary artery catheters in heart failure,[@R11] electronic fetal monitoring in low-risk pregnancies: even then practice can take a decade to reverse.[@R12]

Even good evidence is subject to the phenomenon of reversal where new evidence contradicts current practice. Reversal can affect around 13--16% of publications.[@R5] [@R6] This may partly explain why the implementation of even the most soundly evidence based national guidelines fails to improve outcome.[@R13] There is potential harm[@R16] [@R17] from guidelines in real clinical settings, for example, increasing radiation dose without benefit[@R18] or increased risks of anticoagulation.[@R19]

SIGN 116 (diabetes), is a notable outlier. It is more than 50% larger than the next largest, 2.5 times longer than the average and yet uses the fourth lowest level D recommendations. There are a number of hypotheses why this group reports differently. SIGN guidelines inform QOF policy. Diabetes is the largest clinical UK QOF indicator and is associated with substantial payment incentives. The need for objective evaluation of performance drives a use of surrogate outcomes without appropriate clinical endpoints.[@R20] Diabetes guidelines have suffered several noteworthy reversals. Examples include the recommendation of glycosylated haemoglobin reduction resulting in increased use of rosiglitazone (still mentioned in the current document) both associated with harm including mortality.[@R21] [@R22] Aspirin recommendations have also been changed from previous guidelines. Is it possible that the repeated use of surrogate outcomes arises from group dynamics driven by a powerful external agenda?

Many doctors whose expertise cross several guidelines[@R23] [@R24] express concerns about guideline development groups. The inappropriate exclusion of disease groups from general population data is common. Smoking cessation advice is applicable to the general population almost without exception, yet the evidence to stop smoking was graded as B on 3 occasions and level C and D once each. Interpreting evidence inconsistently in this way may imply group dysfunction. Differently constituted groups, or greater oversight might avoid problems.

In 1993, SIGN guidelines stated intention was to be evidence based, brief and succinct. Brevity increases value as a quick reference guide. Removing or reducing poorly evidenced recommendations would reduce size by more than a third overall and in some up to two-thirds. The two volumes Oxford Textbook of Primary Medical Care (2005) is a relatively brief 1420 pages, more than a 1000 less than the 2559 pages of guidelines. Evidence-based medicine is described as "the use of mathematical estimates of the risk of benefit and harm, derived from high-quality research on population samples, to inform clinical decision-making in the diagnosis, investigation or management of individual patients."[@R25] Guidelines relevance to daily practice, the reliability of evidence and whether the application of evidence will improve outcomes are important questions.

These results may reflect how professional groups deal with uncertainty. If so, this is not good for individual patients faced with the same uncertainties (whether aware of it or not), nor is it good for scientists who actively seek unanswered questions by challenging established practice, an area in which medicine has a poor record from Semmelweis to the present day.

The finding of a significant increase of level D recommendations in larger guidelines has not happened by chance. A wider debate about how guideline groups can create greater clarity about the reliability of evidence used is needed.[@R26] Reducing the use of poorly evidenced recommendations has potential to create a shorter, more reliable and usable clinical support. The GRADE working group was formed in 2000.[@R27] SIGN moved to a new grading system in 2001[@R28] and from 2013 a new system based on GRADE principles. Whether these changes will resolve the challenges that underpin the inconsistencies we have outlined remains to be seen.
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